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The chemokine receptor CCR5 is the most important entry coreceptor for HIV-1 in vivo. Its chemokine
ligands, including CCL3L1, efficiently inhibit infection by receptor blockade and downmodulation.
However, in Nature Immunology, Dolan et al. (2007) present a large human-cohorts study that
identifies entry-independent, CCR5-CCL3L1-dependent effects on cell-mediated immunity as a
strong correlate of pathogenesis and point to additional influences of the CCR5-CCL3L1 axis on
disease progression through undefined mechanisms.CCR5 has been suborned as an entry
coreceptor by primate immunodefi-
ciency viruses (PIV), most notably
HIV-1 (human immunodeficiency virus
type 1). The viral gp120 glycoproteins
bind CCR5 during the events that
drive fusion of the virus and cell mem-
branes, leading to infection (Hart-
ley et al., 2005). CCR5 was probably
the sole receptor for the primordial
PIV from which present-day viruses
evolved, but acquiring the ability to
use CD4 (cluster of differentiation 4)
as a primary receptor prior to CCR5
binding quite plausibly provided ad-
vantages to PIVs. By serving as a
high-affinity binding site on target
cells, CD4 speeds infection, and it
also allows the highly conserved CCR5
site on gp120 to remain shielded
from neutralizing antibodies until too
little time and space remain for suc-
cessful intervention. Hence, CCR5
clearly influences HIV-1 replication,
and a series of genetic studies haveshown it is a major determinant on
the rate of progression of HIV-1-in-
fected individuals to acquired immu-
nodeficiency syndrome (AIDS) and
death. CCR5 expression varies be-
tween individuals, principally because
of sequence variations, within its pro-
moter, that affect protein production;
the less CCR5 expressed, the slower
disease progresses. Moreover, a rare,
protein-inactivating mutation, CCR5-
D32, strongly protects against acqui-
sition of HIV-1 infection by homo-
zygous individuals (heterozygotes are
not protected, but progress to disease
less rapidly) (Kuhmann and Hartley,
2008).
CCR5 has chemokine ligands that
reflect its natural role within the im-
mune system: MIP-1a (CCL3), MIP-1b
(CCL4), and RANTES (CCL5). CCL3L1
and CCL4L1 are variant chemokines
encoded by genes with varying copy
numbers. These chemokines inhibit
CCR5 use by HIV-1 through allostericCell Host & Microbe 2, Nblockade and receptor downmodula-
tion (Figure 1) (Hartley et al., 2005);
the more chemokines present, the less
HIV-1 replicates. Genetic studies show
that the number of CCL3L1 gene
copies, and hence CCL3L1 expression
levels, influences disease progression
(Gonzalez et al., 2005).
But the CCR5-CCL3L1 system also
has other effects on disease progres-
sion. In a major new study in a re-
cent issue of Nature Immunology, over
2000 HIV-1-infected and control indi-
viduals were categorized by CCR5
genotype and CCL3L1 copy number
(Dolan et al., 2007). The combination
of a CCR5 high-expression genotype
with a low CCL3L1 copy number was
designated a high genetic risk; the
converse (low CCR5, high CCL3L1)
was designated a low risk. A high
CCR5-expression genotype com-
bined with a high CCL3L1 copy num-
ber, or low CCR5 with low CCL3L1,
constituted moderate risk categories.ovember 2007 ª2007 Elsevier Inc. 281
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and CCR5-CCL3L1 genetic status
were all good predictors of both time
to AIDS and the slope of CD4+ T cell
decline (Dolan et al., 2007). However,
CCR5-CCL3L1 genetics predicted
that viral load or baseline CD4+ T cell
counts only weakly. The relationship
between cell-surface CCR5 expres-
sion and viral load is complex. In vitro,
HIV-1 entry varies nonlinearly with
CCR5 expression, and the crucial level
of CCR5 is affected by CD4 availabil-
ity; modeling suggests that three to
six CCR5 molecules mediate entry of
a single virion (Kuhmann et al., 2000).
Furthermore, viral load is influenced
by the number of target cells and their
susceptibility to infection, and the
more HIV-1 replicates, the more it
deprives itself of targets for further ex-
pansion. Understanding this helps to
explain the weak covariation between
viral load and CCR5-CCL3L1 status.
How might CCR5-CCL3L1 genetics
influence pathogenesis independently
of HIV-1 entry efficiency and viral cy-
topathic effects on CD4+ T cells?
An obvious possibility is via the cell-
mediated immune (CMI) system. The
adaptive immune response to a virus,
whether humoral or cell mediated, is
also self-attenuating: The more repli-
cation, the stronger the immune re-
sponse, but the stronger the immune
response, the less replication. The
influence of such complexities were
minimized by measurement of a pa-
rameter, delayed type hypersensitivity
(DTH) to unrelated antigens, which
could reflect intrinsic CMI responsive-
ness. A strong inverse correlation was
observed between CCR5-CCL3L1
genetic risk and the strength of the
DTH response; in the HIV-1-infected
cohort, DTH correlated with time to
AIDS and inversely with the CD4+
T cell depletion rate (Dolan et al.,
2007). Finally, after adjustment for the
effect of genetic status on DTH, a re-
sidual viral load- and CMI-indepen-
dent effect of CCR5-CCL3L1 variation
on disease progression was identified
in the HIV-1-infected group (Dolan
et al., 2007). The CCR5-CCL3L1 axis
therefore seems to modulate HIV-1
disease course in three partly indepen-
dent ways, one involving the adaptive
immune system.282 Cell Host & Microbe 2, November 200There has been a perception that
CCR5 plays no role in the immune re-
sponse to pathogens, on the basis of
the observation that the rare humans
(~1% of Caucasians) who are CCR5-
D32 homozygotes and so genetically
lack CCR5 are healthy and live normal
life spans. Moreover, CCR5 knockout
mice are also ‘‘normal,’’ and a signifi-
cant minority of Red-cap mangabeys
genetically lacks CCR5 without overt
consequences. There are, however,
both adverse and beneficial conse-
quences of the absence of CCR5
under some circumstances. Thus, ex-
perimental infection of CCR5 knock-
out mice with various pathogens,
such as Cryptococcus neoformans,
can be lethal, whereas wild-type
mice survive (Huffnagle et al., 1999),
Figure 1. Hypothetical Molecular Model
of Chemokine Bound to its Receptor
Chemokine receptors, e.g., CCR5, have seven
a-helical transmembrane segments (blue cylin-
ders); these are connected by intracellular and
extracellular loops; the amino terminus is on
the outside; the carboxy terminus on the inside
(all in blue). The chemokine, e.g., CCL3L1, has
three b strands and an a-helix (yellow). In the
proposed interaction, the core of the chemo-
kine contacts the extracellular loops, while its
amino-terminal segment inserts itself into the
bundle of helices. This binding has important
consequences for HIV-1 infection and immune
function. It signals via G proteins, blocks the
binding of the HIV-1 envelope glycoprotein al-
losterically, and downmodulates the receptor
from the cell surface. This image was repro-
duced with permission from Blanpain et al.
(2003).7 ª2007 Elsevier Inc.and CCR5-D32 homozygous humans
are at greater risk for lethal infection
by West Nile virus (Glass et al.,
2006). The loss of CCR5 arose in
Northern Europe a few thousand years
ago. The present-day geographic dis-
tribution and allele frequency reflect
population migrations (Viking inva-
sions) and a presumed beneficial
effect of the absence of CCR5 on re-
sistance to another disease, probably
smallpox (although the Black Death
has its proponents). If the absence of
CCR5 can indeed sometimes help
survival, this could be relevant to
the conclusion that the less CCR5
expressed, the stronger the CMI re-
sponse (Dolan et al., 2007). Exactly
how CCR5-CCL3L1 affects CMI re-
sponses to various pathogens, includ-
ing HIV-1, is not known, but Dolan
et al. (2007) note several possible
mechanisms that warrant further in-
vestigation, including effects on T cell
regeneration and the formation of
the immunological synapse. Never-
theless, the beneficial effects of higher
CCL3L1 levels, although complex,
seem more straightforward than those
of reduced CCR5 expression (Molon
et al., 2005).
But what could the entry- and
CMI-independent effects of CCR5-
CCL3L1 be? Here, we can only specu-
late, by pointing out factors that are
probably irrelevant. For example, any
effects of CCR5-CCL3L1 on the size
and susceptibility of the important T
cell reservoir in gut-associated lym-
phoid tissue should be reflected in
the resulting viral load, at least initially,
as should the propensity of infected
and bystander T cells to succumb to
apoptotic or necrotic death, which
would affect CMI as well. Likewise,
modulation of adaptive or innate
immunity that specifically dampens
HIV-1 replication, without registering
as DTH responsiveness, is plausible
but should curb viral load. A switch
from R5 to X4 virus is associated with
increased disease progression but
would not be favored by higher
CCR5 levels. The parasite Toxoplasma
gondii stimulates IL-12 (interleukin 12)
secretion from dendritic cells through
soluble factors that signal via CCR5
(Aliberti et al., 2000), but if this
were a general mechanism, it would
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Previewspresumably benefit host immunity and
correlate directly, rather than inversely,
with CCR5 expression.
Dolan et al. (2007) measure HIV-1
pathogenicity as a loss of CD4+ T cells.
Although many other immune system
aberrations occur during HIV-1 infec-
tion, the elusive residual mechanism
must therefore affect this particular
central parameter. Because replica-
tion of a cytolytic virus is self-attenuat-
ing, fluctuations in viral load might
occur as target cells in gut-associated
lymphoid tissue are depleted early in
infection. Such effects could cloud
any simple correlation between viral
load and the cellular susceptibility to
HIV-1 infection or the rate of cell killing.
Is the explanation for the residual ef-
fects of the CCR5-CCL3L1 axis to be
found in this complexity, or is there a
novel mechanism? The biology under-
lying the new genetic observations
clearly must be explored further. How
CCR5-CCL3L1 affects vaccine re-
sponses is also something to con-
sider because there is considerable
host-dependent variation in immune
responses to HIV-1 vaccine immuno-
gens.
An additional point is that antago-
nists of CCR5 function represent a
new class of drugs for treating HIV-1
infection. Of such small-molecule
CCR5 ligands, Maraviroc was recently
licensed, Vicroviroc is in late stage tri-
als, and others are in development(Kuhmann and Hartley, 2008). In
a few individuals in these trials, the
peripheral blood CD4+ T cell count
increases even when viral load is un-
changed; this effect could be relevant
to the findings of Dolan et al. (2007).
To date, there have been few safety
issues related to any adverse effect
of CCR5 antagonists on immune func-
tion. Yet lingering concerns remain
that interfering with CCR5 could be
problematic under certain circum-
stances, such as infection with West
Nile virus and related pathogens. As
noted above, the complete absence
of CCR5 is a European trait that is
generally neutral or even beneficial to
immune responses against pathogens
that have circulated on that continent
or that still do. This might not be true
in a different protean environment,
such as sub-Saharan Africa. Special
care might therefore need to be taken
if and when CCR5 antagonists are
used in Africa. Although Dolan et al.
(2007) conclude that the less CCR5 is
expressed, the better the CMI re-
sponse, this might not apply equally
to every pathogen, particularly ones
rare in or absent from the study
cohorts.
This comprehensive new study
should help improve our understand-
ing of HIV-1 pathogenesis, susceptibil-
ity, and protective immunity, if only by
revealing what we must learn if we are
to design better immune-based inter-Cell Host & Microbe 2, Nventions in the prevention and treat-
ment arenas.REFERENCES
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